IL17 and IL-23 levels have been determined patients who have RR- serum MS

Basit Öğe Kaydı
dc.contributor.authorTasdemir, N.
dc.date.accessioned2024-04-24T16:15:11Z
dc.date.available2024-04-24T16:15:11Z
dc.date.issued2017
dc.departmentDicle Üniversitesien_US
dc.description23rd World Congress of Neurology (WCN) -- SEP 16-21, 2017 -- Kyoto, JAPANen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipWorld Federat Neurolen_US
dc.identifier.doi10.1016/j.jns.2017.08.3205
dc.identifier.endpage1138en_US
dc.identifier.issn0022-510X
dc.identifier.issn1878-5883
dc.identifier.startpage1138en_US
dc.identifier.urihttps://doi.org/10.1016/j.jns.2017.08.3205
dc.identifier.urihttps://hdl.handle.net/11468/15691
dc.identifier.volume381en_US
dc.identifier.wosWOS:000427450304403
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofJournal of The Neurological Sciences
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleIL17 and IL-23 levels have been determined patients who have RR- serum MSen_US
dc.titleIL17 and IL-23 levels have been determined patients who have RR- serum MS
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu